Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patient with chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue SUPPL. 2, 2003, Pages 12-16

  Ortonne, J P ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Alefacept; CD4+CD45RO+ memory effector T cells; CD8+CD45RO+ memory effector T cells; PASI; Psoriasis

Indexed keywords

ALEFACEPT; CD2 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; FC RECEPTOR; PLACEBO;

ACCESSORY CELL; ANAMNESIS; APOPTOSIS; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BRONCHITIS; CANADA; CHRONIC DISEASE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EUROPE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HERPES SIMPLEX; HUMAN; IMMUNOPATHOGENESIS; INFECTION COMPLICATION; INJURY; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PATIENT SELECTION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD4; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTE ACTIVATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 0037930034     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.17.s2.3.x     Document Type: Article

References (7)

1. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of 'memory' T cells (CD4+, CDw29+) over 'naive' T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989; 281: 24-30.
2. Friedrich M, Krammig S, Henze M, Doecke WD, Sterry W, Asadullah K. Analyzing of lesional T-cells in psoriasis by flowcytometry [abstract]. Annual Meeting; May, 2001, Washington, DC: Society for Investigative Dermatology.
3. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000; 14: 63-78.
4. Miller GT, Hochman PS, Meier W et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-222.
5. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-2767.
6. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
7. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.